DaltonTx
Category: AI in Healthcare
DaltonTx is developing an adaptive, AI-powered platform to serve as the intelligence backbone for drug discovery. DaltonTx was founded in 2024. The company is led by Garry Pairaudeau. Based in London, United Kingdom. Team size: 11-50. Total funding raised: £4 million. Latest round: Seed, £4.0M, 2025-09, led by redalpine. Key investors include redalpine, IQ Capital Partners, Seedcamp.
- Founded
- 2024
- Headquarters
- London, United Kingdom
- Team size
- 11-50
- Total funding
- £4 million
Value proposition
To reshape the economics and timelines of drug discovery by providing a platform with scientific reasoning capabilities that deeply integrates into drug discovery workflows.
Products and solutions
AI-enabled drug discovery platform
Unique value
The company is building an adaptive AI platform with deep integration into scientific workflows, focusing on creating a foundational 'intelligence backbone' for drug discovery rather than a point solution.
Target customer
Pharmaceutical and biotechnology companies.
Industries served
Pharmaceuticals, Biotechnology
Technology advantage
Their advantage lies in the development of an adaptive AI platform that combines deep learning with a profound understanding of the underlying science, led by a team with extensive experience in AI and drug discovery.
How they differentiate
DaltonTx is developing adaptive, AI-enabled discovery platforms intended to serve as the 'intelligence backbone' for pharmaceutical R&D. Their technology is designed to learn from every experiment, aiming to fundamentally change the economics, timelines, and success rates of drug discovery.
Main competitors
Exscientia, BenevolentAI, Healx
Key partnerships
redalpine (investor), IQ Capital (investor), Seedcamp (investor), Cambridge University Innovation (investor)
Notable customers
Information not publicly available.
Major milestones
Founded in 2024., Emerged from stealth mode., Secured £4 million in seed funding., Selected for SLAS Europe 2026 Innovation AveNEW program.
Growth metrics
As a seed-stage company that recently emerged from stealth, public growth metrics are not available.
Market positioning
DaltonTx is an emerging startup targeting pharmaceutical companies, biotech firms, and contract research organizations (CROs) with its AI-powered drug discovery infrastructure.
Geographic focus
United Kingdom (initial focus: UK & Europe)
Patents and IP
Information not publicly available.
About Garry Pairaudeau
Over 30 years of experience in drug discovery, with previous roles including VP of Hit Discovery at AstraZeneca and CTO at Exscientia.
Official website: https://www.daltontx.com/